Amedeo Smart

Free Medical Literature Service

 

Amedeo

HIV Infection
  Free Subscription

Articles published in
J Clin Invest
    April 2024
  1. EICHHOLZ K, Fukazawa Y, Peterson CW, Haeseleer F, et al
    Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers.
    J Clin Invest. 2024;134:e169309.
    >> Share

    March 2024
  2. ELIZALDI SR, Hawes CE, Verma A, Shaan Lakshmanappa Y, et al
    Chronic SIV-induced neuroinflammation disrupts CCR7+CD4+ T cell immunosurveillance in the rhesus macaque brain.
    J Clin Invest. 2024 Mar 12:e175332. doi: 10.1172/JCI175332.
    >> Share

    February 2024
  3. GASCA-CAPOTE C, Lian X, Gao C, Roseto IC, et al
    The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
    J Clin Invest. 2024 Feb 20:e174215. doi: 10.1172/JCI174215.
    >> Share

    January 2024
  4. JONGO S, Church LWP, Milando F, Qassim M, et al
    Safety and protective efficacy of PfSPZ vaccine administered to HIV negative and positive Tanzanian adults.
    J Clin Invest. 2024 Jan 9:e169060. doi: 10.1172/JCI169060.
    >> Share

  5. SHEN XY, Zhang J, Huang HZ, Li SD, et al
    Synapsin 2a/Synaptogyrin-3 interaction regulates fear extinction in mice.
    J Clin Invest. 2024 Jan 4:e172802. doi: 10.1172/JCI172802.
    >> Share

    September 2023
  6. WIETGREFE SW, Anderson J, Duan L, Southern PJ, et al
    Initial productive and latent HIV infections originate in vivo by infection of resting T cells.
    J Clin Invest. 2023 Sep 21:e171501. doi: 10.1172/JCI171501.
    >> Share

  7. DRAGONI F, Kwaa A, Traut CC, Veenhuis RT, et al
    Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones.
    J Clin Invest. 2023 Sep 12:e171097. doi: 10.1172/JCI171097.
    >> Share

    July 2023
  8. MCMYN NF, Varriale J, Fray EJ, Zitzmann C, et al
    The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.
    J Clin Invest. 2023 Jul 18:e171554. doi: 10.1172/JCI171554.
    >> Share

    June 2023
  9. BEKERMAN E, Yant SR, VanderVeen LA, Hansen D, et al
    Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a rectal SHIV challenge macaque model.
    J Clin Invest. 2023 Jun 29:e167818. doi: 10.1172/JCI167818.
    >> Share

  10. TANG Y, Chaillon A, Gianella S, Wong LM, et al
    Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy.
    J Clin Invest. 2023;133:e167417.
    >> Share

    April 2023
  11. PIERCE CA, Loh LN, Steach HR, Cheshenko N, et al
    HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal.
    J Clin Invest. 2023 Apr 20:e164317. doi: 10.1172/JCI164317.
    >> Share

    March 2023
  12. EMERY A, Joseph SB, Swanstrom R
    Nonsuppressible viremia during HIV-1 therapy meets molecular virology.
    J Clin Invest. 2023;133:e167925.
    >> Share

    February 2023
  13. COHEN KW, Fiore-Gartland A, Walsh SR, Yusim K, et al
    Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
    J Clin Invest. 2023;133:e163338.
    >> Share

  14. KENNEDY BD, Blazkova J, Justement JS, Shi V, et al
    Comprehensive analysis of HIV reservoirs in elite controllers.
    J Clin Invest. 2023;133:e165446.
    >> Share

    January 2023
  15. PERDOMO-CELIS F, Passaes C, Monceaux V, Volant S, et al
    Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control.
    J Clin Invest. 2023;133:e167843.
    >> Share

  16. WHITE JA, Wu F, Yasin S, Moskovljevic M, et al
    Clonally expanded HIV-1 proviruses with 5'-Leader defects can give rise to nonsuppressible residual viremia.
    J Clin Invest. 2023 Jan 5:e165245. doi: 10.1172/JCI165245.
    >> Share

    December 2022
  17. KIM JT, Zack JA
    A humanized mouse model to study NK cell biology during HIV infection.
    J Clin Invest. 2022;132:e165620.
    >> Share

  18. PELUSO MJ, Deveau TM, Munter SE, Ryder DM, et al
    Impact of pre-existing chronic viral infection and reactivation on the development of long COVID.
    J Clin Invest. 2022 Dec 1:e163669. doi: 10.1172/JCI163669.
    >> Share

    October 2022
  19. SUNGUR CM, Wang Q, Ozanturk AN, Gao H, et al
    Human natural killer cells confer protection against HIV-1 infection in humanized mice.
    J Clin Invest. 2022 Oct 25. pii: 162694. doi: 10.1172/JCI162694.
    >> Share

  20. SHI G, Chiramel AI, Li T, Lai KK, et al
    Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2.
    J Clin Invest. 2022 Oct 20. pii: 160766. doi: 10.1172/JCI160766.
    >> Share

    August 2022
  21. FOX DA
    Immunodeficiency and autoimmunity: companions not opposites.
    J Clin Invest. 2022;132.
    >> Share

    July 2022
  22. GRUDDA T, Hwang HS, Taddese M, Quinn J, et al
    Integrated hepatitis B virus DNA maintains surface antigen production during antivirals.
    J Clin Invest. 2022 Jul 7. pii: 161818. doi: 10.1172/JCI161818.
    >> Share

    June 2022
  23. TAKATA H, Trautmann L
    Transforming dysfunctional CD8+ T cells into natural controller-like CD8+ T cells: can TCF-1 be the magic wand?
    J Clin Invest. 2022;132.
    >> Share

    May 2022
  24. BALLE C, Armistead B, Kiravu A, Song X, et al
    Factors influencing maternal microchimerism throughout infancy and its impact on infant T cell immunity.
    J Clin Invest. 2022 May 12. pii: 148826. doi: 10.1172/JCI148826.
    >> Share

    April 2022
  25. FALCINELLI SD, Peterson JJ, Turner AW, Irlbeck D, et al
    Combined noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.
    J Clin Invest. 2022;132.
    >> Share

  26. PERDOMO-CELIS F, Passaes C, Monceaux V, Volant S, et al
    Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control.
    J Clin Invest. 2022 Apr 5. pii: 157549. doi: 10.1172/JCI157549.
    >> Share

  27. LEYRE L, Jones RB
    Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity.
    J Clin Invest. 2022;132:1-4.
    >> Share

    March 2022
  28. VARCO-MERTH BD, Brantley W, Marenco A, Duell DD, et al
    Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy.
    J Clin Invest. 2022 Mar 22. pii: 156063. doi: 10.1172/JCI156063.
    >> Share

  29. FERRARI B, Da Silva AC, Liu KH, Saidakova EV, et al
    Gut-derived bacterial toxins impair memory CD4 T-cell mitochondrialfunction in HIV-1infection.
    J Clin Invest. 2022 Mar 22. pii: 149571. doi: 10.1172/JCI149571.
    >> Share

  30. HARPER J, Ribeiro SP, Chan CN, Aid M, et al
    Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy.
    J Clin Invest. 2022 Mar 1. pii: 155251. doi: 10.1172/JCI155251.
    >> Share

    February 2022
  31. DUETTE G, Hiener B, Morgan H, Mazur FG, et al
    The HIV-1 proviral landscape reveals Nef contributes to HIV-1 persistence in effector memory CD4+ T-cells.
    J Clin Invest. 2022 Feb 8. pii: 154422. doi: 10.1172/JCI154422.
    >> Share

  32. ARMSTRONG E, Hemmerling A, Miller S, Burke KE, et al
    Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli.
    J Clin Invest. 2022 Feb 3. pii: 152930. doi: 10.1172/JCI152930.
    >> Share

    December 2021
  33. SHARAN R, Ganatra SR, Bucsan AN, Cole J, et al
    Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a tuberculosis/simian immunodeficiency virus coinfection model.
    J Clin Invest. 2021 Dec 2. pii: 153090. doi: 10.1172/JCI153090.
    >> Share

  34. CAMPION SL, Brenna E, Thomson E, Fischer W, et al
    Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.
    J Clin Invest. 2021;131.
    >> Share

    November 2021
  35. SCULLY EP, Bryson BD
    Unlocking the complexity of HIV and Mycobacterium tuberculosis coinfection.
    J Clin Invest. 2021;131.
    >> Share

  36. MITCHELL JL, Pollara J, Dietze K, Edwards RW, et al
    Anti-HIV antibody development up to one year after antiretroviral therapy initiation in acute HIV infection.
    J Clin Invest. 2021 Nov 11. pii: 150937. doi: 10.1172/JCI150937.
    >> Share

    October 2021
  37. LI M, Garforth SJ, O'Connor KE, Su H, et al
    T-cell receptor-specific immunotherapeutics drive selective in vivo HIV and CMV-specific T-cell expansion in humanized mice.
    J Clin Invest. 2021 Oct 21. pii: 141051. doi: 10.1172/JCI141051.
    >> Share

  38. PETERSON CW
    HIV-specific CAR T cells return to the clinic.
    J Clin Invest. 2021;131.
    >> Share

    September 2021
  39. QUINN TC
    Forty years of AIDS: a retrospective and the way forward.
    J Clin Invest. 2021;131.
    >> Share

  40. DIAS J, Fabozzi G, March K, Asokan M, et al
    Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.
    J Clin Invest. 2021;131.
    >> Share

    August 2021
  41. MENDEZ-LAGARES G, Chin N, Chang WLW, Lee J, et al
    Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function.
    J Clin Invest. 2021;131.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016